6 active not recruiting, 3 completed. 6 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 3, Completed 3 |
| Phase 1 | 2 | Active not recruiting 2 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Stage III Urethral Cancer AJCC v8: new trials by email Literature Review of Stage III Urethral Cancer AJCC v8 trials Research Report on Stage III Urethral Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study Avelumab, Biospecimen Collection, Bone Scan - Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 654 | 2022-06-03 | 2026-10-26 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
| ARID1A and/or KDM6A Mutation and CXCL13 Expression Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 6 | 2021-09-21 | 2026-10-06 |
| Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Atezolizumab, Biopsy, Biospecimen Collection - Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2019-06-05 | 2024-07-26 |
| Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate Carboplatin, Cisplatin, Docetaxel - Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 15 | 2019-01-11 | 2025-11-12 |
| Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer Avelumab, Cisplatin, Fluorouracil - Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8 | Phase 2 | Completed | Mayo Clinic | 2 | 2018-09-19 | 2023-01-06 |
| Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Atezolizumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 72 | 2018-07-20 | 2026-07-31 |
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 152 | 2015-07-22 | 2026-10-15 |
| Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer Erlotinib Hydrochloride - Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 34 | 2008-06-10 | 2020-09-10 |
Urethral Neoplasms (9) · Urinary Bladder Neoplasms (9) · Ureteral Neoplasms (8) · Carcinoma, Transitional Cell (3) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Lung Neoplasms (1) · Melanoma (1) · Penile Neoplasms (1) · Prostatic Neoplasms (1) · Urogenital Neoplasms (1)
Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Male Urogenital Diseases (9) · Neoplasms (9) · Neoplasms by Site (9) · Urethral Diseases (9) · Urinary Bladder Diseases (9) · Urogenital Diseases (9) · Urologic Diseases (9) · Urologic Neoplasms (9) · Ureteral Diseases (8) · Urogenital Neoplasms (8) · Neoplasms by Histologic Type (5) · Carcinoma (4) · Neoplasms, Glandular and Epithelial (4)
Specimen Handling (4) · Biopsy (3) · Magnetic Resonance Spectroscopy (3) · Nivolumab (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · CTLA-4 Antigen (2) · Cisplatin (2) · Ipilimumab (2) · Platinum (2) · atezolizumab (2) · avelumab (2) · cabozantinib (2) · Carboplatin (1) · Contrast Media (1) · Disulfides (1)
National Cancer Institute (NCI) (4) · M.D. Anderson Cancer Center (3) · Jonsson Comprehensive Cancer Center (1) · Mayo Clinic (1)
United States (9) · Canada (1)
Andrea B Apolo (1) · Anishka A D'Souza (1) · Arlene Siefker-Radtke (1) · Arnold Chin (1) · Evan Y Yu (1) · Parminder Singh (1) · Rodabe Amaria, MD (1) · Sangeeta Goswami (1) · Shilpa Gupta (1)
PMID 32915679, PMID 35031545, PMID 35537412, PMID 37328287, PMID 38954785, PMID 39536751
UM1CA186717 (2), P30CA015704 (1), P30CA016672 (1), U01CA154967 (1), U10CA180821 (1), UM1CA186712 (1), UM1CA186716 (1), ZIABC011078 (1)